Artificial intelligence in Barrett's oesophagus and the need for shared and combined data

Affiliations

¹ Department of Internal Medicine I and Institute of Computational Neuroscience and Department of Interdisciplinary Endoscopy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
² Else Kroener Fresenius Center for Digital Health, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.

Editorial

Rüdiger Schmitz et al. United European Gastroenterol J. 2022 Jul.

. 2022 Jul;10(6):525-527.

doi: 10.1002/ueg2.12260. Epub 2022 Jun 15.

¹ Department of Internal Medicine I and Institute of Computational Neuroscience and Department of Interdisciplinary Endoscopy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
² Else Kroener Fresenius Center for Digital Health, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany.

No abstract available

Conflict of interest statement

Jakob N. Kather declares consulting services for Owkin, France, and Panakeia, UK. Rüdiger Schmitz has no conflict of interest to disclose.

A new artificial intelligence system successfully detects and localises early neoplasia in Barrett's esophagus by using convolutional neural networks.
Hussein M, González-Bueno Puyal J, Lines D, Sehgal V, Toth D, Ahmad OF, Kader R, Everson M, Lipman G, Fernandez-Sordo JO, Ragunath K, Esteban JM, Bisschops R, Banks M, Haefner M, Mountney P, Stoyanov D, Lovat LB, Haidry R. Hussein M, et al. United European Gastroenterol J. 2022 Jul;10(6):528-537. doi: 10.1002/ueg2.12233. Epub 2022 May 6. United European Gastroenterol J. 2022. PMID: 35521666 Free PMC article.

1. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high‐grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105(1):40–50. 10.1016/0016-5085(93)90008-Z - DOI - PubMed
1. Klaver E, Bureo Gonzalez A, Mostafavi N, Mallant‐Hent R, Duits LC, Baak B, et al. Barrett’s esophagus surveillance in a prospective Dutch multi‐center community‐based cohort of 985 patients demonstrates low risk of neoplastic progression. United Eur Gastroenterol J. 2021;9(8):929–37. 10.1002/ueg2.12114 - DOI - PMC - PubMed
1. Abrams JA, Kapel RC, Lindberg GM, Saboorian MH, Genta RM, Neugut AI, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009;7(7):736–42. 10.1016/j.cgh.2008.12.027 - DOI - PMC - PubMed
1. Duits LC, Phoa KN, Curvers WL, ten Kate FJW, Meijer GA, Seldenrijk CA, et al. Barrett’s oesophagus patients with low‐grade dysplasia can Be accurately risk‐stratified after histological review by an expert pathology panel. Gut. 2015;64(5):700–6. 10.1136/gutjnl-2014-307278 - DOI - PubMed
1. Parasa S, Vennalaganti S, Gaddam S, Vennalaganti P, Young P, Gupta N, et al. Development and validation of a model to determine risk of progression of Barrett’s esophagus to neoplasia. Gastroenterology. 2018;154(5):1282–9. e2. 10.1053/j.gastro.2017.12.009 - DOI - PubMed